Edition:
India

Aptinyx Inc (APTX.OQ)

APTX.OQ on NASDAQ Stock Exchange Global Select Market

4.05USD
8:46pm IST
Change (% chg)

$0.03 (+0.75%)
Prev Close
$4.02
Open
$4.04
Day's High
$4.12
Day's Low
$4.04
Volume
5,440
Avg. Vol
59,561
52-wk High
$31.16
52-wk Low
$2.88

Latest Key Developments (Source: Significant Developments)

Aptinyx Reports Qtrly Loss Per Share Of $0.50
Tuesday, 14 May 2019 

May 14 (Reuters) - Aptinyx Inc ::APTINYX REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.APTINYX INC - FOUR PHASE 2 STUDIES EXPECTED TO BE ONGOING BY YEAR END; MULTIPLE DATA READ-OUTS ANTICIPATED IN 2019 AND 2020.APTINYX INC QTRLY LOSS PER SHARE $0.50.APTINYX INC - CASH AND CASH EQUIVALENTS WERE $136.6 MILLION AT MARCH 31, 2019 COMPARED TO $150.6 MILLION AT DECEMBER 31, 2018..  Full Article

Aptinyx Reports Robust Analgesic Activity Of Its NYX-2925 In Advanced DPN Patients
Thursday, 18 Apr 2019 

April 18 (Reuters) - Aptinyx Inc ::ROBUST ANALGESIC ACTIVITY OF APTINYX’S NYX-2925 IN ADVANCED DPN PATIENTS REVEALED THROUGH FURTHER ANALYSIS OF DATA FROM PHASE 2 STUDY.APTINYX INC - RESULTS SUPPORT AND INFORM FUTURE PHASE 2 STUDY, INITIATION EXPECTED IN 2019.APTINYX INC - MECHANISM OF NYX-2925 IS HIGHLY RELEVANT IN ADVANCED DPN PATIENTS WITH LONGER DURATION OF CHRONIC PAIN.  Full Article

Aptinyx Q4 Loss Per Share $0.42
Thursday, 21 Mar 2019 

March 21 (Reuters) - Aptinyx Inc ::APTINYX REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND HIGHLIGHTS PIPELINE AND BUSINESS PROGRESS.Q4 LOSS PER SHARE $0.42.Q4 EARNINGS PER SHARE ESTIMATE $-0.50 -- REFINITIV IBES DATA.COMPLETED PHASE 2 STUDY OF NYX-2925 IN PAINFUL DPN WHICH DID NOT MEET PRIMARY ENDPOINT.INITIATED FIRST-IN-PATIENT PHASE 2A STUDY OF NYX-783 IN PATIENTS WITH PTSD WITH DATA EXPECTED IN 1H 2020.NEARING COMPLETION OF PHASE 1 STUDY OF NYX-458 IN HEALTHY VOLUNTEERS WITH DATA EXPECTED IN 1H 2019.CASH AND CASH EQUIVALENTS WERE $150.6 MILLION AT DECEMBER 31, 2018 COMPARED TO $92.1 MILLION AT DECEMBER 31, 2017..  Full Article

Aptinyx Inc Initiates Phase 2 Study To Evaluate Safety And Efficacy Of NYX-783 In Patients With Post-Traumatic Stress Disorder
Tuesday, 19 Feb 2019 

Feb 19 (Reuters) - Aptinyx Inc ::APTINYX INITIATES PHASE 2 STUDY TO EVALUATE SAFETY AND EFFICACY OF NYX-783 IN PATIENTS WITH POST-TRAUMATIC STRESS DISORDER.APTINYX INC - PHASE 2 DATA ANTICIPATED 1H 2020.APTINYX INC - DOSED FIRST PATIENT IN A PHASE 2 STUDY OF NYX-783 FOR TREATMENT OF POST-TRAUMATIC STRESS DISORDER.APTINYX INC - FAVORABLE SAFETY AND TOLERABILITY, LINEAR PHARMACOKINETICS, AND AMPLE CNS EXPOSURE OF NYX-783 OBSERVED IN PHASE 1.  Full Article

Aptinyx Sees IPO Of 5.3 Mln Shares Priced To Be Between $14 And $16 Per Share – SEC Filing
Monday, 11 Jun 2018 

June 11 (Reuters) - Aptinyx Inc ::APTINYX INC SEES IPO OF 5.3 MILLION SHARES PRICED TO BE BETWEEN $14 AND $16 PER SHARE – SEC FILING.  Full Article